10-NOV-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4169 362 175 92 25 5 02/06/2019 485 188
Screened at PD     1598 240 116 61 15 3      
Pre-Screened prior to PD     2542 106 51 28 8 2      
Treatment-naive     29 16 8 3 2 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     544 26 11 8 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2308 298 138 65 19 3      
Screened at PD     1364 242 116 57 16 3      
Pre-Screened prior to PD     856 34 12 4 1 0      
Treatment-naive     29 18 8 3 2 0      
After PD on a Lung_MAP Sub-Study     59 4 2 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     482 252 113 53 10 1      
S1900G     43 11 8 2 2 0      
S1900K     49 25 11 5 4 1      
S1900N     6 6 6 5 3 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     694 147 73 32 12 0      
Initial sub-study registrations     681 146 72 32 12 0      
Subsequent sub-study registrations     13 1 1 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 153 119 60 26 9 0 05/22/2025 362 120
Docetaxel plus Ramucirumab Y   76 58 27 10 3 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   77 61 33 16 6 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 29 7 4 1 1 0 05/05/2023 340 107
Capmatinib + Osimertinib + Ramucirumab Y   16 4 2 0 0 0      
Capmatinib + Osimertinib Y   13 3 2 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 32 18 7 3 1 0 08/08/2024 298 92
Tepotinib + Ramucirumab Y   22 13 6 2 1 0      
Tepotinib Y   10 5 1 1 0 0      
S1900N: AGAs: SG alone, I alone, or SG + I   117 2 2 2 2 1 0 09/22/2026 236 62
Sacituzumab Govitecan + Ivonescimab Y   1 1 1 1 1 0      
Sacituzumab Govitecan Y   1 1 1 1 0 0